Page 1

Fourth - Quarter 2020 and Full Year Results West Full Year Overall Net Sales $ 2.147B | 16.7 % Diluted Earnings Per Share : $ 4.57 | ↑ 42 % Adjusted Diluted Earnings Per Share : $ 4.76 | ✩47 % " We had a successful 2020 with tremendous execution , dedication and resiliency of our team and , most importantly , the trust of our customers across the globe . I am proud that we finished the year with record full - year net sales , organic sales growth and operating profit margin . Fourth quarter results were robust , led by strong growth in our Biologics and Generics market units . In addition , we experienced an acceleration in COVID - 19 - associated sales of high - value product ( HVP ) components used for vaccines and therapeutics . As we look ahead , we believe there is strong momentum in our base business and uptake of our HVP components and devices . We will continue to operate with excellence and a sense of urgency to maintain the supply of life - saving solutions that our customers , and ultimately patients , rely upon during these challenging times . " Eric M. Green President and Chief Executive Officer West Pharmaceutical Services , Inc. OVERALL ORGANIC SALES GROWTH Proprietary Products Q4 2020 organic sales growth of 25.1 % , led by sales of high - value products , which grew double digits BIOLOGICS GENERICS R PHARMA CONTRACT MANUFACTURING Q4 19.8 % DD DD LSD MSD Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 Abbreviations : LSD - low - single digit ; MSD - mid - single digit ; HSD - high - single digit ; DD - double digit This presentation and any accompanying management commentary contain " forward - looking statements " as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements include , but are not limited to , statements about product development and operational performance . Each of these statements is based preliminary information , and actual results could differ from any preliminary estimates . We caution investors that the risk factors listed under " Cautionary Statement " in our press releases , as well as those set forth under the caption " Risk Factors " in our most recent Annual Report on Form 10 - K as filed with the Securities and Exchange Commission and as revised or supplemented by our quarterly reports on Form 10 - Q , could cause our actual results to differ materially from those estimated or predicted in the forward - looking statements . You should evaluate any statement in light of these important factors . Except as required by law or regulation , we undertake no obligation to publicly update any forward - looking statements , whether as a result of new information , future events , or otherwise . Non - U.S . GAAP Financial Measures Certain financial measures included in these presentation materials , or which may be referred to in management's discussion of the Company's results and outlook , have not been calculated in accordance with U.S. generally accepted accounting principles ( " U.S. GAAP " ) , and therefore are referred to as non- U.S. GAAP financial measures . Non - U.S . GAAP financial measures should not be considered in isolation or as an alternative to such measures determined in accordance with U.S. GAAP . Please refer to " Reconciliation of Non - U.S . GAAP Financial Measures " at the end of these materials for more information . WST Q4 / FY 2020 Earnings 1